FLT3 and acute myeloid leukemia: These agents are generally well tolerated compared with traditional cytotoxic agents, unfortunately, like many tyrosine kinase inhibitors, their single-agent clinical activity has been modest and major clinical responses in AML patients receiving single-agent FLT3 inhibitors have been rare.